C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 108, Issue 3, 2015, Pages 441-447

  Nishimura, Takeshi ^a   Meguro, Shu ^a   Sekioka, Risa ^a   Tanaka, Karin ^a   Saisho, Yoshifumi ^a   Irie, Junichiro ^a   Tanaka, Masami ^a   Kawai, Toshihide ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

C peptide; Haemoglobin A1c protein; Human; Long term effect; Sitagliptin

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG RESPONSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMMUNOREACTIVITY; INSULIN RESPONSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME;

EID: 84930180756     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.02.031     Document Type: Article

References (27)

1. U.K.Prospective Diabetes Study Group U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258.
2. Fukushima M., Suzuki H., Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004, 66:S37-S43.
3. Fukushima M., Usami M., Ikeda M., Nakai Y., Taniguchi A., Matsuura T., et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004, 53:831-835.
4. Karagiannis T., Paschos P., Paletas K., Matthews D.R., Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012, 344:e1369.
5. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
6. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
7. Pratley R.E., Jauffret-Kamel S., Galbreath E., Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006, 38:423-428.
8. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G., Sitagliptin Study 020 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
9. Takabe M., Matsuda T., Hirota Y., Hashimoto N., Nakamura T., Sakaguchi K., et al. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment. Diabetes Res Clin Pract 2012, 98:e32-e35.
10. Davis D., Kern T., Rand L.I. Diabetic retinopathy. International textbook of diabetes mellitus 1997, 1413-1446. John Wiley & Sons, Chichester, UK. 2nd ed. K.G.M.M. Alberti, P. Zimmet, R.A. DeFronzo (Eds.).
11. Saisho Y., Miyakoshi K., Tanaka M., Shimada A., Ikenoue S., Kadohira I., et al. Beta cell dysfunction and its clinical significance in gestational diabetes. Endocr J 2010, 57:973-980.
12. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y., Nanjo K., Tajima N., Kadowaki T., Kashiwagi A., et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010, 1:212-228.
13. Weykamp C., John W.G., Mosca A., Hoshino T., Little R., Jeppsson J.O., et al. The IFCC Reference Measurement System for HbA1c: a 6-year progress report. Clin Chem 2008, 54:240-248.
14. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
15. Saisho Y., Kou K., Tanaka K., Abe T., Kurosawa H., Shimada A., et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 2011, 58:315-322.
16. Takeda Y., Fujita Y., Honjo J., Yanagimachi T., Sakagami H., Takiyama Y., et al. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 2012, 55:404-412.
17. Williams-Herman D., Johnson J., Teng R., Golm G., Kaufman K.D., Goldstein B.J., et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:442-451.
18. Foley J.E., Bunck M.C., Möller-Goede D.L., Poelma M., Nijpels G., Eekhoff E.M., et al. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011, 54:1985-1991.
19. Harashima S.I., Ogura M., Tanaka D., Fukushima T., Wang Y., Koizumi T., et al. Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract 2012, 66:465-476.
20. Nonaka K., Kakikawa T., Sato A., Okuyama K., Fujimoto G., Kato N., et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 79:291-298.
21. Ahrén B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010, 3:31-41.
22. Williams-Herman D., Engel S.S., Round E., Johnson J., Golm G.T., Guo H., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010, 10:7.
23. Kim Y.G., Hahn S., Oh T.J., Kwak S.H., Park K.S., Cho Y.M. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013, 56:696-708.
24. Esposito K., Chiodini P., Capuano A., Maiorino M.I., Bellastella G., Giugliano D. Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine 2014, 46:43-51.
25. Kim S.A., Shim W.H., Lee E.H., Lee Y.M., Beom S.H., Kim E.S., et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J 2011, 35:159-165.
26. Nomiyama T., Akehi Y., Takenoshita H., Nagaishi R., Terawaki Y., Nagasako H., et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012, 95:e27-e28.
27. Kubota A., Yabe D., Kanamori A., Kuroe A., Takahashi N., Saito T., et al. Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. J Diabetes Invest 2014, 5:445-448.